Author

Jean-Frédéric Colombel

RAPID CLINICAL RESPONSE TO UPADACITINIB THERAPY IS ASSOCIATED WITH IMPROVED CLINICAL AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE
RAPID CLINICAL RESPONSE TO UPADACITINIB THERAPY IS ASSOCIATED WITH IMPROVED CLINICAL AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE

Jean-Frédéric Colombel  et al.

RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES
RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES

Jean-Frédéric Colombel  et al.

EFFECT OF UPADACITINIB ON EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE
EFFECT OF UPADACITINIB ON EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE

Jean-Frédéric Colombel  et al.

THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 DEMONSTRATES RAPID SYMPTOMATIC AND BIOMARKERS IMPROVEMENT IN ULCERATIVE COLITIS: RESULTS IN A PHASE 1B STUDY
THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 DEMONSTRATES RAPID SYMPTOMATIC AND BIOMARKERS IMPROVEMENT IN ULCERATIVE COLITIS: RESULTS IN A PHASE 1B STUDY

Jean-Frédéric Colombel  et al.

MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN
MAINTENANCE OF REMISSION WITH TOFACITINIB IN PATIENTS WITH ULCERATIVE COLITIS: FINAL RESULTS OF A SUBPOPULATION ANALYSIS FROM AN OPEN-LABEL, LONG-TERM EXTENSION STUDY, OCTAVE OPEN

Jean-Frédéric Colombel  et al.

RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES
RISANKIZUMAB INDUCTION THERAPY PROVIDES EARLY SYMPTOM IMPROVEMENTS IN ABDOMINAL PAIN AND STOOL FREQUENCY IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM TWO PHASE 3 INDUCTION STUDIES

RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE
BASELINE AND EARLY PREDICTORS OF RESPONSE TO RISANKIZUMAB INDUCTION AND MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE

Jean-Frédéric Colombel  et al.

SAFETY OF CONCURRENT ADMINISTRATION OF OZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS
SAFETY OF CONCURRENT ADMINISTRATION OF OZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS

Jean-Frédéric Colombel  et al.

SAFETY OF CONCURRENT ADMINISTRATION OF OZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS
SAFETY OF CONCURRENT ADMINISTRATION OF OZANIMOD AND SEROTONERGIC ANTIDEPRESSANTS IN PATIENTS WITH ULCERATIVE COLITIS

Which clinical targets have the potential to change the natural course of IBD? (Takeda)
Which clinical targets have the potential to change the natural course of IBD? (Takeda)

Jean-Frédéric Colombel  et al.

EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY
EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A RANDOMIZED PHASE 3 U-EXCEL STUDY

Jean-Frédéric Colombel  et al.

IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY
IMPACT OF INFLAMMATORY BURDEN ON EFFICACY OF UPADACITINIB MAINTENANCE THERAPY IN ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 U-ACHIEVE STUDY

Jean-Frédéric Colombel  et al.

SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY
SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE: POST HOC ANALYSIS OF LIBERTY-UC STUDY AND LIBERTY-CD STUDY

Jean-Frédéric Colombel  et al.

Achieving control in Crohn's disease: today and tomorrow (Takeda) (Complete Session)
Achieving control in Crohn's disease: today and tomorrow (Takeda) (Complete Session)

Jean-Frédéric Colombel  et al.

EFFICACY OF UPADACITINIB FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE BY DISEASE DURATION: A POST HOC ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES
EFFICACY OF UPADACITINIB FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE BY DISEASE DURATION: A POST HOC ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Jean-Frédéric Colombel  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Jean-Frédéric Colombel  et al.

EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL
EFFECT OF OZANIMOD TREATMENT AND DISCONTINUATION ON ABSOLUTE LYMPHOCYTE COUNT IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM A PHASE 3 RANDOMIZED TRIAL

Jean-Frédéric Colombel  et al.

RADIOLOGIC EVALUATION OF FILGOTINIB TREATMENT IN PERIANAL FISTULIZING CROHN’S DISEASE USING A NOVEL SCORING SYSTEM
RADIOLOGIC EVALUATION OF FILGOTINIB TREATMENT IN PERIANAL FISTULIZING CROHN’S DISEASE USING A NOVEL SCORING SYSTEM

Jean-Frédéric Colombel  et al.

SAFETY, PHARMACOKINETICS, AND IMMUNOLOGICAL EFFECTS OF OMILANCOR (BT-11) IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH ULCERATIVE COLITIS
SAFETY, PHARMACOKINETICS, AND IMMUNOLOGICAL EFFECTS OF OMILANCOR (BT-11) IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH ULCERATIVE COLITIS

Jean-Frédéric Colombel  et al.

Item 1 - 20 / 30
1
2